Navigation Links
Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
Date:2/23/2011

DEERFIELD, Ill. and OSAKA, Japan, February 23, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone (CLD) for the treatment of hypertension, or high blood pressure. Discovered by Takeda, azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. Chlorthalidone is a long-acting oral thiazide-like diuretic used in the treatment of hypertension. The NDA submission was supported by four phase 3 clinical trials involving more than 4,000 patients with hypertension.

“Millions of patients with hypertension do not have their condition under control,” said Darryl Sleep, M.D., vice president, clinical science, Takeda Global Research & Development Center, Inc. U.S. “We believe this compound, the first in the U.S. to combine an ARB with chlorthalidone, could potentially provide an important new treatment option for patients with hypertension and the health care providers who manage them.”

In a phase 3 clinical trial, azilsartan medoxomil (20 mg/day, 40 mg/day and 80 mg/day), combined in a fixed-dose with CLD (12.5 mg/day and 25 mg/day), was studied versus azilsartan medoxomil and CLD monotherapies. In other studies, the fixed-dose combination of azilsartan medoxomil plus CLD was compared to azilsartan medoxomil coadministered with hydrochlorothiazide (HCTZ), another diuretic, and with a fixed-dose combination of olmesartan medoxomil and HCTZ.

Results from a phase 3 clinical trial of the fixed-dose combination of azilsartan medoxomil plus CLD were previously presented at the American Society of Hypertension, Inc. (ASH), 25th Annual Scientific Meeting and Expositio
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc., U.S.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
2. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
3. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
4. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Takeda Responds to FDA Advisory Committee Recommendation
7. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
8. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
9. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
11. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... MELVILLE, N.Y. , Sept. 16, 2014 /PRNewswire/ ... ), the world,s largest provider of health care ... and medical practitioners, announced today that Stanley M. ... Officer, will participate in a healthcare services panel ... 2014.  Joining Mr. Bergman will be Dr. Stohler, ...
(Date:9/16/2014)... 16, 2014  Eli Lilly and Company (NYSE: ... an agreement to co-develop and commercialize AZD3293, an ... in development as a potential treatment for Alzheimer,s ... is characterized by the accumulation of amyloid plaque ... with the development of beta-amyloid. Inhibiting BACE is ...
(Date:9/16/2014)... , N.J. and NEW PROVIDENCE, N.J. , ... experts will present a paper on the critical elements ... oxygen storage and deliver systems at the American Society ... be held at the Chicago Sheraton Hotel and Towers ... Derrick West , program manager of Hospital ...
Breaking Medicine Technology:Henry Schein To Present At The Leerink Partners Services Roundtable 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 2Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 3
... LAKE FOREST, Ill. , Jan. 22 Hospira, ... and medication delivery company, and its philanthropic arm, the Hospira Foundation, ... medical products and cash grants to support humanitarian relief efforts in ... at more than $1.5 million , are either in ...
... SOMERVILLE, N.J. , Jan. 20 ... acquisition of Acclarent, Inc., following clearance under the Hart-Scott-Rodino ... technology company dedicated to designing, developing and commercializing devices ... (ENT). Ethicon announced its agreement to acquire Acclarent ...
Cached Medicine Technology:Hospira Supports Disaster Relief Efforts in Haiti With Products and Cash Grants 2
(Date:9/16/2014)... 16, 2014 After working together for eight ... the premier fertility centers in the late 1990s and early ... to their hometown of New York City to launch Chelsea ... Genetics Labs. , Chelsea Fertility NYC offers full service ... in the New York Tri-State Area, and provides equal access ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Emotional eaters ... hungry, but for comfort during times of stress, loneliness, ... sugar laden treats that may provide temporary relief, but ... sabotaging the best laid weight loss goals. Fortunately, Diet ... that provide patients with the skills and alternatives to ...
(Date:9/16/2014)... 2014 Current students of Ramtha’s School ... in Yelm, Washington, Oct. 20-26 to further their studies. ... caps off the remarkable “Masters of Divine Jazz” World ... Italy, Australia, South Korea, Mexico, and South Africa. Cost ... children ages 6-19 and for seniors age 65 and ...
(Date:9/16/2014)... 2014 With Pfister Energy Inc as ... Antonio, TX. has been awarded a solar technology contract ... US, including Alaska and Hawaii, U.S. Territories and the ... (EITF) and the Corps of Engineers, Engineering and Support ... to fund renewable and alternative energy projects greater than ...
(Date:9/16/2014)... Dr. Randy Carlson and ... Love Your Marriage event is coming to the ... married couples to better communicate, increase intimacy and have more ... of fun, encouragement and learning to strengthen your marriage and ... – Living Word Bible Church (Mesa), Saturday, Sept. 27 – ...
Breaking Medicine News(10 mins):Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 4Health News:Diet Doc Announces Emotional Eaters Diet Plans to Help Patients Break the Cycle for Fast and Permanent Weight Loss 2Health News:Diet Doc Announces Emotional Eaters Diet Plans to Help Patients Break the Cycle for Fast and Permanent Weight Loss 3Health News:Ramtha School Presents Capstone Event in Yelm Oct. 20-26 2Health News:Solar Construction Opportunity at U.S Army Installations Awarded to Pfister Energy & Infinity Development 2Health News:The Intentional Living Center Introduces the Love Your Marriage Night Featuring Dr. Randy Carlson in Arizona 2
... a threeat to the globe as 95% of the ... Nations General Assembly Special Session on HIV/AIDS, physicians demanded ... that would cater the AIDS victims in developing countries. ... borders (commonly known as Medicines Sans Frontieres, or MSF), ...
... 41st Annual Conference on Cardiovascular Disease Epidemiology and Prevention ... counterpart to heart disease-Asthma. It is found that asthma ... MD, MPH, PhD, of Kaiser Permanente, in his study ... risk of 33% towards developing the heart disease than ...
... of psychological benefits, including fighting stress-related physical and mental ... no psychological benefit from the use of ginseng. ... sport and exercise psychology lab at the Oregon State ... PhD, conducted the study and found that there was ...
... of the major cause of morbidity in most of ... be reluctant to take extra vitamins or iron pills, ... candies were effective for improving the iron status of ... combat iron deficiency in children of low-to-middle income groups. ...
... of the nervous system due to the progressive gradual ... involuntary movements and balance problems and later on leading ... ,All these days, until now, it was thought that ... the protein 'huntingtin' which is responsible for destroying the ...
... India has launched an oral treatment for smoking, called ... reportedly the first product aimed at stopping smoking and ... to newspersons, Mr. Kalyanasundaram, Director (Pharmaceuticals), Glaxo India Ltd, ... takes about 7-12 weeks. ,In the first year ...
Cached Medicine News:Health News:Asthma! A new warning for heart disease 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
... The BacT/Alert 3D Signature is ... microbial detection system that integrates blood, ... It is a powerful microbiology workstation ... for higher volume identification and where ...
Medicine Products: